These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 22985614

  • 21. Thrombin-activatable fibrinolysis inhibitor levels in patients with non-small-cell lung cancer.
    Koldas M, Gummus M, Seker M, Seval H, Hulya K, Dane F, Kural A, Gumus A, Salepci T, Turhal NS.
    Clin Lung Cancer; 2008 Mar; 9(2):112-5. PubMed ID: 18501098
    [Abstract] [Full Text] [Related]

  • 22. Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
    Antovic JP, Blombäck M.
    Thromb Res; 2002 Apr 01; 106(1):59-62. PubMed ID: 12165290
    [Abstract] [Full Text] [Related]

  • 23. Tissue factor pathway inhibitor and thrombin-activatable carboxypeptidase B for prediction of early atherosclerosis in gouty arthritis.
    Uyanik MS, Pamuk GE, Pamuk ON, Tuncel SA.
    Thromb Res; 2014 Aug 01; 134(2):526-30. PubMed ID: 24974054
    [Abstract] [Full Text] [Related]

  • 24. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1.
    Meltzer ME, Lisman T, de Groot PG, Meijers JC, le Cessie S, Doggen CJ, Rosendaal FR.
    Blood; 2010 Jul 08; 116(1):113-21. PubMed ID: 20385790
    [Abstract] [Full Text] [Related]

  • 25. Lys 42/43/44 and Arg 12 of thrombin-activable fibrinolysis inhibitor comprise a thrombomodulin exosite essential for its antifibrinolytic potential.
    Wu C, Stafford AR, Fredenburgh JC, Weitz JI, Gils A, Declerck PJ, Kim PY.
    Thromb Haemost; 2017 Jul 26; 117(8):1509-1517. PubMed ID: 28640323
    [Abstract] [Full Text] [Related]

  • 26. Thrombin-activatable fibrinolysis inhibitor in hypothyroidism and hyperthyroxinaemia.
    Verkleij CJ, Stuijver DJ, van Zaane B, Squizzato A, Brandjes DP, Büller HR, Meijers JC, Gerdes VE.
    Thromb Haemost; 2013 Feb 26; 109(2):214-20. PubMed ID: 23197299
    [Abstract] [Full Text] [Related]

  • 27. A new pedigree with thrombomodulin-associated coagulopathy in which delayed fibrinolysis is partially attenuated by co-inherited TAFI deficiency.
    Westbury SK, Whyte CS, Stephens J, Downes K, Turro E, Claesen K, Mertens JC, Hendriks D, Latif AL, Leishman EJ, NIHR BioResourceNIHR BioResource, Cambridge University Hospitals, Cambridge, UK., Mutch NJ, Tait RC, Mumford AD.
    J Thromb Haemost; 2020 Sep 26; 18(9):2209-2214. PubMed ID: 32634856
    [Abstract] [Full Text] [Related]

  • 28. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe.
    Juhan-Vague I, Morange PE, Aubert H, Henry M, Aillaud MF, Alessi MC, Samnegård A, Hawe E, Yudkin J, Margaglione M, Di Minno G, Hamsten A, Humphries SE, HIFMECH Study Group.
    Arterioscler Thromb Vasc Biol; 2002 May 01; 22(5):867-73. PubMed ID: 12006404
    [Abstract] [Full Text] [Related]

  • 29. Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A.
    Antovic J, Schulman S, Eelde A, Blombäck M.
    Haemophilia; 2001 Nov 01; 7(6):557-60. PubMed ID: 11851753
    [Abstract] [Full Text] [Related]

  • 30. Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor.
    Bajzar L, Nesheim M, Morser J, Tracy PB.
    J Biol Chem; 1998 Jan 30; 273(5):2792-8. PubMed ID: 9446587
    [Abstract] [Full Text] [Related]

  • 31. Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels.
    Santamaría A, Oliver A, Borrell M, Mateo J, Belvis R, Martí-Fábregas J, Ortín R, Tirado I, Souto JC, Fontcuberta J.
    Stroke; 2003 Oct 30; 34(10):2387-91. PubMed ID: 12947154
    [Abstract] [Full Text] [Related]

  • 32. Assessment of plasminogen activator inhibitor-1(PAI1) and thrombin activitable fibrinolysis inhibitor (TAFI) in Egyptian children with hemophilia A.
    Soliman M, Osman N, Hefnawy S, El Hawy MA.
    Pediatr Hematol Oncol; 2022 May 30; 39(4):318-328. PubMed ID: 34668834
    [Abstract] [Full Text] [Related]

  • 33. A challenging issue in COVID-19 infection: The relationship between PA1-1 and TAFI levels in patients with coagulation disorder: A retrospective and observational study.
    Altin N, Tiğlioğlu P, Ulusoy TU, Aydin FN, Kar İ, Karakoc B, Utebey G.
    Medicine (Baltimore); 2024 Apr 12; 103(15):e37802. PubMed ID: 38608056
    [Abstract] [Full Text] [Related]

  • 34. A comprehensive study on hemostasis in CAPD patients treated with erythropoietin.
    Malyszko J, Suchowierska E, Malyszko JS, Mysliwiec M.
    Perit Dial Int; 2002 Apr 12; 22(5):582-92. PubMed ID: 12455569
    [Abstract] [Full Text] [Related]

  • 35. Plasma levels of free tissue factor pathway inhibitor in patients with various thyroid disorders.
    Ozcan MA, Cömlekçi A, Demirkan F, Yüksel F, Sari I, Demir T, Ozsan GH, Orük G, Yeşil S, Undar B.
    Thromb Res; 2003 Jun 01; 110(4):243-7. PubMed ID: 14512089
    [Abstract] [Full Text] [Related]

  • 36. Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin.
    Mosnier LO, Meijers JC, Bouma BN.
    Thromb Haemost; 2001 Jan 01; 85(1):5-11. PubMed ID: 11204587
    [Abstract] [Full Text] [Related]

  • 37. The profibrinolytic effect of plasma thrombomodulin in factor XI deficiency and its implications in hemostasis.
    Dai L, Mitchell M, Savidge G, Alhaq A.
    J Thromb Haemost; 2004 Dec 01; 2(12):2200-4. PubMed ID: 15613027
    [Abstract] [Full Text] [Related]

  • 38. Activation of endothelial cells, coagulation and fibrinolysis in children with Dengue virus infection.
    Sosothikul D, Seksarn P, Pongsewalak S, Thisyakorn U, Lusher J.
    Thromb Haemost; 2007 Apr 01; 97(4):627-34. PubMed ID: 17393026
    [Abstract] [Full Text] [Related]

  • 39. Tissue factor pathway inhibitor and thrombin activatable fibrinolytic inhibitor plasma levels following burn and septic injuries in rats.
    Ravindranath TM, Goto M, Demir M, Tobu M, Kujawski MF, Hoppensteadt D, Samonte V, Iqbal O, Sayeed MM, Fareed J.
    Clin Appl Thromb Hemost; 2004 Oct 01; 10(4):379-85. PubMed ID: 15497025
    [Abstract] [Full Text] [Related]

  • 40. Circulating levels of plasminogen activator inhibitor type-1, tissue plasminogen activator, and thrombomodulin in hemodialysis patients: biochemical correlations and role as independent predictors of coronary artery stenosis.
    Segarra A, Chacón P, Martinez-Eyarre C, Argelaguer X, Vila J, Ruiz P, Fort J, Bartolomé J, Camps J, Moliner E, Pelegrí A, Marco F, Olmos A, Piera L.
    J Am Soc Nephrol; 2001 Jun 01; 12(6):1255-1263. PubMed ID: 11373350
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.